Hydroxychloroquine May Worsen Odds for Cancer Patients With
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
As the evidence piles up that a malaria drug touted as a possible coronavirus treatment by may instead harm patients, a new study shows the same might hold true for cancer patients with COVID-19.

Researchers found that cancer patients with COVID-19 who receive both hydroxychloroquine and the antibiotic azithromycin have a higher risk of death than those who aren't given the two drugs.

Of the 928 patients in the study, 13% died within 30 days of being diagnosed with COVID-19. After adjusting for certain factors, the researchers concluded that patients with progressing cancer were 5.2 times more likely to die within 30 days than those in remission or with no evidence of cancer.

Patients who received the combination of hydroxychloroquine and azithromycin to treat COVID-19 had a nearly threefold higher risk of death within 30 days than those who didn't receive either drug, the investigators found.

Patients who received the two drugs and later died were more likely to: have had slightly reduced daily physical function; have received cancer therapy less than 2 weeks before being diagnosed with COVID-19; have Rh-positive blood type; be of non-Hispanic ethnicity; and to be taking cholesterol-lowering statins.

The study will be presented virtually at the annual meeting of the American Society of Clinical Oncology (ASCO).

Source: https://www.medpagetoday.com/meetingcoverage/asco/86738
a●●●●h g●●●a and 3 others like this3 shares
Dr. S●●●●●m S●●●●y P●●●●●l
Dr. S●●●●●m S●●●●y P●●●●●l General Medicine
Very interesting. So the irony is,the very drugs which are actually even today being given as maybe the only drugs working against Covid 19,has a faster toxicity effect on the cancer comorbid patients than if no such treatment was given at all. The lack of replication of results even between acclaimed research groups across even developed nations raises serious questions on the falling levels of basic research and lack of transparency,funds and autonomy to institutes carrying out such results.... Read more
May 30, 2020Like3